215 studies found for:    nash
Show Display Options
Rank Status Study
1 Unknown  Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
Condition: Non-Alcoholic Steatohepatitis
Intervention:
2 Recruiting Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab;   Biological: Placebo
3 Unknown  Pentoxifylline Versus Pioglitazone In Non-Alcoholic Steatohepatiti (NASH)
Condition: Metabolic Parameters and Liver Histology
Interventions: Drug: Pioglitazone;   Drug: Pentoxifylline
4 Completed The Role of Leptin Receptors in NASH
Conditions: Nonalcoholic Steatohepatitis;   Metabolic Syndrome
Intervention: Other: no interventions, only regular blood-draw
5 Completed The Effect of Protandim on Non-alcoholic Steatohepatitis
Condition: Non-Alcoholic Steatohepatitis
Interventions: Dietary Supplement: Protandim;   Dietary Supplement: Placebo
6 Terminated
Has Results
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Conditions: Nonalcoholic Steatohepatitis (NASH);   Hepatic Steatosis
Interventions: Drug: Omega-3-acid ethyl esters (Lovaza);   Drug: Placebo
7 Completed Omega 3 Supplementation in Fatty Liver
Condition: Fatty Liver
Intervention: Dietary Supplement: Omega 3
8 Unknown  Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH
Conditions: Nonalcoholic Steatohepatitis;   Liver Diseases
Intervention: Drug: Pentoxifylline
9 Recruiting Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Condition: Nonalcoholic Steatohepatitis
Interventions: Drug: placebo;   Drug: pioglitazone;   Dietary Supplement: Vitamin E
10 Active, not recruiting The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
Conditions: Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Interventions: Drug: obeticholic acid;   Drug: placebo
11 Active, not recruiting Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis
Condition: Non Alcoholic Fatty Liver Diseases (NAFLD)
Intervention:
12 Recruiting Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GR-MD-02;   Drug: Placebo
13 Completed Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH
Condition: Non-Alcoholic Steatohepatitis(NASH)
Interventions: Drug: Active treatment;   Drug: Placebo
14 Active, not recruiting Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
15 Completed Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Conditions: Non-alcoholic Steatohepatitis;   Fatty Liver
Interventions: Drug: Omega 3 Fish Oil supplements;   Drug: Placebo
16 Recruiting Simtuzumab (GS-6624) in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab 75 mg;   Biological: Simtuzumab 125 mg;   Biological: Placebo
17 Completed Exploratory Study to Assess the Short Term Effect on Liver Enzymes and the Safety of TRO19622 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Intervention: Drug: TRO19622
18 Completed Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
Conditions: Hepatic Cirrhosis;   Nonalcoholic Steatohepatitis
Intervention: Drug: NRL972
19 Terminated An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes
Condition: Fatty Liver
Interventions: Drug: rimonabant (SR141716);   Drug: Placebo
20 Terminated An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
Condition: Fatty Liver
Interventions: Drug: rimonabant (SR141716);   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years